Pseudomembranous Colitis Surgery

Pseudomembranous Colitis Surgery

No Results

No Results


Pseudomembranous colitis is an acute inflammatory disease of the colon that in mild cases may appear as minimal inflammation or edema of the colonic mucosa. In more severe cases, the mucosa often is covered with loosely adherent nodular or diffuse exudates. These raised exudative plaques are 2-5 mm in size. Coalescence of these plaques generates an endoscopic appearance of yellowish pseudomembranes lining the colonic mucosa.

In the late 1800s, before the availability of antibiotics, Finney reported the first case of pseudomembranous colitis, calling it “diphtheritic colitis.” [1] Hall and O’Toole first described Clostridium difficile in 1935. [2] C difficile was first implicated as a causative factor in pseudomembranous colitis in the 1970s. Over the past 100 years, pseudomembranous colitis has changed from a fatal disease caused by a postoperative event to, in the era of antibiotics, a commonly occurring complication of antibiotic use that may lead to serious morbidity but that usually is treated easily. [3]

See Can’t-Miss Gastrointestinal Diagnoses, a Critical Images slideshow, to help diagnose the potentially life-threatening conditions that present with gastrointestinal symptoms.

Pseudomembranous colitis is an inflammatory disease of the colon. In some cases (5-19%), the disease is localized to the cecum and the proximal colon.

The antibiotic-induced change in the balance of normal gut flora allows overgrowth of C difficile. [4] Colitis results from the bacterial production of large amount of toxins. The most important toxins are toxin A (enterotoxin) and toxin B (cytotoxin). One theory explains the variable severity of clinical disease through differential production rates of one toxin or the other by selected bacterial isolates. Most experts, however, believe that these variations are due to host factors.

The toxins bind to the mucosa, attack the membranes and the microfilaments of the mucosal cells, and subsequently result in cytoplasmic contraction, hemorrhage, inflammation, cellular necrosis, and protein loss. They also interfere with mucosal protein synthesis, stimulate granulocyte chemotaxis, and increase capillary permeability, intestinal myoelectric responses, and peristalsis. Intestinal tissue invasion by C difficile has been reported in fatal cases of pseudomembranous colitis in pediatric patients with hematologic malignancy.

Pseudomembranous colitis usually is associated with antibiotic use, which may alter the balance of normal gut flora and allow overgrowth of certain organisms. [4]  Clindamycin, lincomycin, ampicillin, and cephalosporin have been implicated in most of the reported cases, but any antimicrobial agent (including antifungal, antiviral, and metronidazole) could incite the disease, regardless of the amount administered or the route of administration.

C difficile, a gram-positive, spore-forming, anaerobic bacillus, is isolated in almost all of these cases. Rare cases have been related to Staphylococcus aureus, Salmonella species, Clostridium perfringens, Yersinia species, Shigella species, Campylobacter species, cytomegalovirus, Entamoeba histolytica, and Listeria species.

Conditions other than antimicrobial administration could predispose to C difficile pseudomembranous colitis. Such conditions include bowel ischemia, recent bowel surgery, uremia, dietary change, change in bowel motility, malnutrition, chemotherapy, shock, and Hirschsprung disease.

The incidence of antibiotic-associated diarrhea ranges from 5% to 39%, depending on the antibiotic type. Pseudomembranous colitis complicates 10% of cases of antibiotic-associated diarrhea. C difficile is found in the stool of 15-25% of asymptomatic, antibiotic-treated, hospitalized adults. Similar numbers were found in debilitated patients and in patients who received one dose of prophylactic antibiotics before surgical procedure.

C difficile is an unusual component of healthy bowel flora. It is found in 3-5% of healthy adults; however, as many as 50% of infants and children harbor the bacteria and its toxins. Pseudomembranous colitis is a surprisingly rare disease in infants and young children—a population recognized as frequent asymptomatic colonizers. The low incidence of colitis in the pediatric population is attributed to the strength of the immune system. Antibodies to C difficile frequently are detected in infected young patients.

About 25% of human C difficile isolates are nontoxigenic. C difficile colitis is the fourth most common nosocomial disease reported to the Centers for Disease Control and Prevention. C difficile is one of the most frequently isolated enteric pathogens, second only to Campylobacter jejuni. [5]

High-risk populations [6] include elderly people, patients in the intensive care unit (ICU), people with uremia, people with burns, people undergoing abdominal surgery, women undergoing cesarean delivery, and patients with cancer. One suggestion is that these patients do not have greater susceptibility to the disease but are at heightened risk of nosocomial infection. C difficile can be transmitted nosocomially, via the hands of personnel or by contaminated objects. It can survive in spore form for as long as 5 months on hospital floors.

The overall mortality for pseudomembranous colitis is 2%. The mortality in untreated elderly or debilitated patients is 10-20%. Even with surgical intervention, mortality and morbidity in patients with toxic megacolon remain high (35% and 66%, respectively). [7]

Finney JMT. Gastro-enterostomy for cicatrizing ulcer of the pylorus. Johns Hopkins Hosp Bull. 1893. 4:53-55.

Hall IC, O’Toole E. Intestinal flora in new-born infants. Am J Dis Child. 1935. 49:390-402.

Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA. 2015 Jan 27. 313 (4):398-408. [Medline].

McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 2008 Oct. 3:563-78. [Medline].

Indra A, Lassnig H, Baliko N, et al. Clostridium difficile: a new zoonotic agent?. Wien Klin Wochenschr. 2009 Feb. 121(3-4):91-95. [Medline].

Greenstein AJ, Byrn JC, Zhang LP, et al. Risk factors for the development of fulminant Clostridium difficile colitis. Surgery. 2008 May. 143(5):623-9. [Medline].

Mitas L, Svaton R, Skricka T, Kala Z, Penka I, Hanslianov M, et al. Surgical treatment of Clostridium colitides. Acta Chir Iugosl. 2012. 59(2):63-9. [Medline].

Earhart MM. The identification and treatment of toxic megacolon secondary to pseudomembranous colitis. Dimens Crit Care Nurs. 2008 Nov-Dec. 27(6):249-54. [Medline].

Kelly CP. A 76-year-old man with recurrent Clostridium difficile-associated diarrhea: review of C. difficile infection. JAMA. 2009 Mar 4. 301(9):954-62. [Medline].

Zheng L, Keller SF, Lyerly DM, Carman RJ, Genheimer CW, Gleaves CA, et al. Multicenter evaluation of a new screening test that detects Clostridium difficile in fecal specimens. J Clin Microbiol. 2004 Aug. 42(8):3837-40. [Medline].

Vigna SR. 5-Aminosalicylic Acid Inhibits Acute Clostridium difficile Toxin A-Induced Colitis in Rats. Int J Inflam. 2014. 2014:389621. [Medline].

McVey DC, Liddle RA, Riggs-Sauthier J, Ekwuribe N, Vigna SR. Inhibition of Clostridium difficile toxin A-induced colitis in rats by APAZA. Dig Dis Sci. 2005 Mar. 50(3):565-73. [Medline].

Vigna SR. Intraluminal Administration of Resiniferatoxin Protects against Clostridium difficile Toxin A-Induced Colitis. Gastroenterol Res Pract. 2017. 2017:8438172. [Medline]. [Full Text].

Cornely OA, Miller MA, Fantin B, Mullane K, Kean Y, Gorbach S. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol. 2013 Jul 1. 31(19):2493-9. [Medline].

Juang P, Skledar SJ, Zgheib NK, et al. Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea. Am J Infect Control. 2007 Mar. 35(2):131-7. [Medline].

Salcedo J, Keates S, Pothoulakis C, et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut. 1997 Sep. 41(3):366-70. [Medline]. [Full Text].

Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013 Apr. 108(4):500-8. [Medline].

Staley C, Hamilton MJ, Vaughn BP, Graiziger CT, Newman KM, Kabage AJ, et al. Successful Resolution of Recurrent Clostridium difficile Infection using Freeze-Dried, Encapsulated Fecal Microbiota; Pragmatic Cohort Study. Am J Gastroenterol. 2017 Jun. 112 (6):940-947. [Medline].

Cammarota G, Masucci L, Ianiro G, Bibbò S, Dinoi G, Costamagna G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015 May. 41 (9):835-43. [Medline].

Gerding DN, Meyer T, Lee C, Cohen SH, Murthy UK, Poirier A, et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA. 2015 May 5. 313 (17):1719-27. [Medline].

Longo WE, Mazuski JE, Virgo KS, et al. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum. 2004 Oct. 47(10):1620-6. [Medline].

Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting Loop Ileostomy and Colonic Lavage: An Alternative to Total Abdominal Colectomy for the Treatment of Severe, Complicated Clostridium difficile Associated Disease. Ann Surg. 2011 Sep. 254(3):423-9. [Medline].

Ferrada P, Callcut R, Zielinski MD, Bruns B, Yeh DD, Zakrison TL, et al. Loop ileostomy versus total colectomy as surgical treatment for Clostridium difficile-associated disease: An Eastern Association for the Surgery of Trauma multicenter trial. J Trauma Acute Care Surg. 2017 Jul. 83 (1):36-40. [Medline].

Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med. 2017 Jan 26. 376 (4):305-317. [Medline]. [Full Text].

Said Fadi Yassin, MD Associate Professor of Surgery, Department of Cardiothoracic Surgery, University of New Mexico School of Medicine

Said Fadi Yassin, MD is a member of the following medical societies: Society of Thoracic Surgeons

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Amy L Friedman, MD Professor of Surgery, Director of Transplantation, State University of New York Upstate Medical University College of Medicine, Syracuse

Amy L Friedman, MD is a member of the following medical societies: Association for Academic Surgery, International College of Surgeons, New York Academy of Sciences, Pennsylvania Medical Society, Philadelphia County Medical Society, Society of Critical Care Medicine, Association of Women Surgeons, International Liver Transplantation Society, Transplantation Society, American College of Surgeons, American Medical Association, American Medical Womens Association, American Society for Artificial Internal Organs, American Society of Transplant Surgeons, American Society of Transplantation

Disclosure: Nothing to disclose.

John Geibel, MD, DSc, MSc, AGAF Vice Chair and Professor, Department of Surgery, Section of Gastrointestinal Medicine, Professor, Department of Cellular and Molecular Physiology, Yale University School of Medicine; Director of Surgical Research, Department of Surgery, Yale-New Haven Hospital; American Gastroenterological Association Fellow

John Geibel, MD, DSc, MSc, AGAF is a member of the following medical societies: American Gastroenterological Association, American Physiological Society, American Society of Nephrology, Association for Academic Surgery, International Society of Nephrology, New York Academy of Sciences, Society for Surgery of the Alimentary Tract

Disclosure: Nothing to disclose.

H Scott Bjerke, MD, FACS Clinical Associate Professor, Department of Surgery, University of Missouri-Kansas City School of Medicine; Medical Director of Trauma Services, Research Medical Center; Clinical Professor, Department of Surgery, Kansas City University of Medicine and Biosciences

H Scott Bjerke, MD, FACS is a member of the following medical societies: American Association for the History of Medicine, American Association for the Surgery of Trauma, American College of Surgeons, Midwest Surgical Association, Royal Society of Medicine, Eastern Association for the Surgery of Trauma, Association for Academic Surgery, National Association of EMS Physicians, Pan-Pacific Surgical Association, Southwestern Surgical Congress, Wilderness Medical Society

Disclosure: Nothing to disclose.

Pseudomembranous Colitis Surgery

Research & References of Pseudomembranous Colitis Surgery|A&C Accounting And Tax Services